MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.69
-0.08
-0.58%
Opening 11:06 01/29 EST
OPEN
13.73
PREV CLOSE
13.77
HIGH
13.86
LOW
13.63
VOLUME
45.84K
TURNOVER
--
52 WEEK HIGH
29.17
52 WEEK LOW
11.83
MARKET CAP
730.18M
P/E (TTM)
6.14
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VNDA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VNDA News

  • Vanda Pharmaceuticals Option Alert: Mar 20 $16 Calls at the Ask: 1000 @ $1.101 vs 230 OI; Earnings 2/12 After Close [est] Ref=$15.1
  • Benzinga.01/21 17:41
  • Vandas patent challenge over its schizophrenia drug is finally over. But it's not their only generics threat.
  • American City Business Journals.01/16 19:57
  • Vanda Pharmaceuticals Wins U.S. Supreme Court Patent Ruling On Fanapt; Order By U.S. Supreme Court Ensures That '610 Patent Will Remain Exclusive At Least Through November 2, 2027
  • Reuters.01/13 19:16
  • Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
  • PR Newswire.01/13 19:11

More

Industry

Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.43%

Hot Stocks

Name
Price
%Change

About VNDA

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
More

Webull offers Vanda Pharmaceuticals Inc. (VNDA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.